Medon Clinical Research Sp. z o.o.
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
The research team at Medon Clinical Research is evaluating new treatments for bacterial vaginosis, a common vaginal infection, with the goal of offering safer and equally effective options.
- Comparison of a novel vaginal tablet (furazidin) with the standard clindamycin cream
- Assessment of patient‑reported outcomes and symptom relief
- Focus on non‑inferiority to ensure comparable effectiveness
This work supports the site’s commitment to advancing women's health in Warsaw.
Cardiovascular Diseases
At this site, investigators are addressing major heart‑related risks in individuals with atherosclerotic cardiovascular disease, chronic kidney disease, and heart failure with preserved or mildly reduced ejection fraction.
- Evaluation of a novel oral agent (orforglipron) for reducing major cardiovascular events
- Study of a weekly injectable (NNC0487‑0111) aimed at lowering heart‑failure hospitalisations and improving outcomes in patients with obesity
- Monitoring of cardiovascular death, urgent visits, and quality‑of‑life measures
These trials reflect Medon Clinical Research’s focus on innovative cardiovascular therapies for high‑risk populations.
Digestive System Diseases
The center conducts multiple studies on inflammatory bowel diseases, specifically moderate to severe Crohn’s disease and ulcerative colitis, seeking to induce and maintain clinical remission.
- Induction trial of a biologic agent (RO7790121) in Crohn’s disease
- Evaluation of another investigational therapy (RO7837195) for ulcerative colitis remission
- Comprehensive adult and adolescent programs testing icotrokinra for both induction and maintenance phases
Results aim to expand therapeutic options for patients suffering from chronic gastrointestinal inflammation.
Immune System Diseases
Research efforts target disorders driven by dysregulated immunity, with a particular emphasis on inflammatory bowel conditions and related immune‑mediated diseases.
- Investigation of immune‑modulating biologics such as icotrokinra to achieve sustained remission
- Exploration of biomarkers that predict response to therapy in ulcerative colitis and Crohn’s disease
- Safety monitoring of long‑term immune suppression in adult and adolescent cohorts
The work underscores the site’s dedication to improving outcomes for patients with immune‑related illnesses.
Immune System Phenomena
Studies at Medon Clinical Research delve into the underlying immune mechanisms that drive disease activity, providing a foundation for precision medicine.
- Characterization of cytokine profiles associated with treatment response
- Assessment of cellular immune pathways in heart failure and inflammatory bowel disease
- Integration of immunological data to refine patient selection for targeted therapies
These investigations help translate immunological insights into actionable clinical strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Janssen Cilag International2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medon Clinical Research Sp. z o.o.
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Janssen Cilag International | Phase IV | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| ICOTROKINRA | 2 | Unknown | 2025-12-03 | 2025-12-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.